FLGT - Company ID 0001674930
Fulgent Genetics, Inc. trades as FLGT. In its fiscal 2025 annual report the company posted revenue of $322.67M, up 13.8% from the prior year and net income of -$60.51M. This page tracks Fulgent Genetics, Inc. through 636 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
With latest filings
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Over the last 9 fiscal years Fulgent Genetics, Inc.'s revenue grew from $18.28M to $322.67M, a compound annual growth rate of 37.6%. Net profit margin expanded from -29.3% to -18.8% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13D/A | - | 2026-05-27 |
| Insider trade | 4 | 2026-05-27 |
| Major company event | 8-K | 2026-05-21 |
| Insider trade | 4 | 2026-05-18 |
| Insider trade | 4 | 2026-05-18 |
| Insider trade | 4 | 2026-05-18 |
| Employee stock plan | S-8 | 2026-05-14 |
| Major company event | 8-K | 2026-05-14 |
The largest companies sharing Fulgent Genetics, Inc.'s SEC industry classification (services-medical laboratories).
Fulgent Genetics, Inc. reported revenue of $322.67M for fiscal year 2025, an increase of 13.8% year over year.
In its latest fiscal year Fulgent Genetics, Inc. reported a net loss of $60.51M.